|
Apr 18
|
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
|
|
Apr 18
|
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
|
|
Apr 9
|
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
|
|
Mar 24
|
11 Best ASX Stocks To Buy Now
|
|
Nov 30
|
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
|
|
Nov 30
|
Here's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Compensation Is The Least Of Shareholders Concerns
|
|
Aug 11
|
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering
|
|
Aug 9
|
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
|